Search results for "clinical neurology"

showing 10 items of 95 documents

Headache in epilepsy: prevalence and clinical features

2015

Background Headache and epilepsy are two relatively common neurological disorders and their relationship is still a matter of debate. Our aim was to estimate the prevalence and clinical features of inter-ictal (inter-IH) and peri-ictal headache (peri-IH) in patients with epilepsy. Methods All patients aged ≥ 17 years referring to our tertiary Epilepsy Centre were consecutively recruited from March to May 2011 and from March to July 2012. They underwent a semi-structured interview including the International Classification Headache Disorders (ICHD-II) criteria to diagnose the lifetime occurrence of headache.χ2-test, t-test and Mann–Whitney test were used to compare clinical variables in pati…

AdultMalemedicine.medical_specialtyNeurologyAdolescentCross-sectional studyClinical NeurologyPost-ictal headacheEpilepsyYoung AdultPrimary headacheInternal medicinePrevalenceMedicineHumansIn patientYoung adultStrokeMigraineAgedAged 80 and overPre-ictal headacheEpilepsybusiness.industryHeadacheGeneral MedicineMiddle Agedmedicine.diseaseclinical featurenervous system diseasesStrokeAnesthesiology and Pain MedicineCross-Sectional Studiesnervous systemMigraineAnesthesiaFemaleNeurology (clinical)businessResearch ArticleThe Journal of Headache and Pain
researchProduct

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, par…

2011

Medication-overuse headache (MOH) represents a severely disabling condition, with a low response to prophylactic treatments. Recently, consistent evidences have emerged in favor of botulinum toxin type-A (onabotulinum toxin A) as prophylactic treatment in chronic migraine. In a 12-week double-blind, parallel group, placebo-controlled study, we tested the efficacy and safety of onabotulinum toxin A as prophylactic treatment for MOH. A total of 68 patients were randomized (1:1) to onabotulinum toxin A (n = 33) or placebo (n = 35) treatment and received 16 intramuscular injections. The primary efficacy end point was mean change from baseline in the frequency of headache days for the 28-day per…

AdultMalemedicine.medical_specialtyNeurologyOriginalPain medicineClinical NeurologyBotulinum toxin type-APlaceboInjections Intramuscularlaw.inventionChronic MigraineRandomized controlled trialDouble-Blind MethodlawmedicineHumansBotulinum Toxins Type AAdverse effectMuscle SkeletalBotulinum toxin type-A; Medication-overuse headache; Prophylactic treatment; Migraine; Pericranial muscle tendernessMigraineAgedAnalgesicsbusiness.industrySkullHeadacheGeneral MedicineMiddle Agedmedicine.diseaseBotulinum toxinMedication-overuse headacheAnesthesiology and Pain MedicinePericranial muscle tendernessMigraineNeuromuscular AgentsAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessProphylactic treatmentmedicine.drugThe journal of headache and pain
researchProduct

Modulation of pain perception by transcranial magnetic stimulation of left prefrontal cortex.

2010

Evidence by functional imaging studies suggests the role of left dorsolateral prefrontal cortex (DLPFC) in the inhibitory control of nociceptive transmission system. Repetitive transcranial magnetic stimulation (rTMS) is able to modulate pain response to capsaicin. In the present study, we evaluated the effect of DLPFC activation (through rTMS) on nociceptive control in a model of capsaicin-induced pain. The study was performed on healthy subjects that underwent capsaicin application on right or left hand. Subjects judged the pain induced by capsaicin through a 0–100 VAS scale before and after 5 Hz rTMS over left and right DLPFC at 10 or 20 min after capsaicin application in two separate gr…

AdultMalemedicine.medical_specialtyNeurologyOriginalmedicine.medical_treatmentPain medicineClinical NeurologyPainPrefrontal CortexStimulationbehavioral disciplines and activitiesFunctional Lateralitymental disordersmedicineHumansPain ManagementPrefrontal cortexPain Measurementbusiness.industryNeural InhibitionGeneral MedicineMiddle Agedpain perception tms prefrontal cortexTranscranial Magnetic StimulationTranscranial magnetic stimulationFunctional imagingNociceptionAnesthesiology and Pain Medicinenervous systemBrain stimulationAnesthesiaFemaleMagnetic stimulationNeurology (clinical)Capsaicinbusinesspsychological phenomena and processesThe journal of headache and pain
researchProduct

An examination of the psychometric structure of the Multidimensional Pain Inventory in temporomandibular disorder patients: a confirmatory factor ana…

2006

Abstract Background This paper seeks to analyse the psychometric and structural properties of the Multidimensional Pain Inventory (MPI) in a sample of temporomandibular disorder patients. Methods The internal consistency of the scales was obtained. Confirmatory Factor Analysis was carried out to test the MPI structure section by section in a sample of 114 temporomandibular disorder patients. Results Nearly all scales obtained good reliability indexes. The original structure could not be totally confirmed. However, with a few adjustments we obtained a satisfactory structural model of the MPI which was slightly different from the original: certain items and the Self control scale were elimina…

AdultMalemedicine.medical_specialtylcsh:Specialties of internal medicinePsychometricsAdolescentPsychometricsClinical NeurologyPainlcsh:RC581-951MedicineHumansTranslationsGeneral DentistryAgedPain MeasurementDentistry(all)business.industryResearchTemporomandibular disorderReproducibility of ResultsMiddle AgedTemporomandibular Joint DisordersConfirmatory factor analysisOtorhinolaryngologySpainHead and neck surgeryPhysical therapyPain psychologyMultidimensional pain inventoryFemaleNeurology (clinical)businessFactor Analysis StatisticalHead & Face Medicine
researchProduct

Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, …

2012

The objective of the study was to compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double-blind, cross-over study. Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient was switched to the other treatment. 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were…

AdultTime FactorsOriginalMigraine DisordersPopulationAlmotriptanClinical NeurologyCarbazolesSubgroup analysisSeverity of Illness IndexAdult; Carbazoles; Cross-Over Studies; Disability Evaluation; Double-Blind Method; Female; Humans; Italy; Menstruation Disturbances; Middle Aged; Migraine Disorders; Proportional Hazards Models; Serotonin Receptor Agonists; Severity of Illness Index; Time Factors; Treatment Outcome; TryptaminesDisability EvaluationDouble-Blind MethodAlmotriptanSeverity of illnessMedicineHumanseducationMigraine Menstrually related migraine Frovatriptan AlmotriptanMenstrually related migraineMenstruation DisturbancesMigraineMenstrually related migraineProportional Hazards Modelseducation.field_of_studyCross-Over Studiesbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseCrossover studyTryptaminesSerotonin Receptor Agonistsfrovatriptan; migraine; menstrually related migraine; almotriptanAnesthesiology and Pain MedicineTreatment OutcomeMigraineItalyAnesthesiaFemaleNeurology (clinical)businessFrovatriptanFrovatriptanmedicine.drug
researchProduct

Alexithymic characteristics in pediatric patients with primary headache: a comparison between migraine and tension-type headache

2015

Background: Alexithymia is a personality construct characterized by difficulties in verbal emotional expression and a limited ability to use one’s imagination. Evidence of alexithymic characteristics was found in adults suffering from headache, while little is known about children. The aim of this study was to establish the prevalence of alexithymia in two different subgroups of children and adolescents suffering from primary headache. We also looked for correlation between alexithymia in children and in their mothers. Methods: This study involved 89 participants: 47 (11 males, 36 females, aged 8 to 17 years) suffering from tension-type headache (TTH), and 42 (18 males, 24 females, aged 8 t…

AlexithymiaMaleAlexithymia; Alexithymia Questionnaire for Children; Migraine; Tension-type headache; Toronto Alexithymia ScaleToronto Alexithymia ScaleAlexithymiaMigraine DisorderSurveys and QuestionnairesPrevalenceSurveys and QuestionnaireEmotional expressionChildmedia_commonMothermedicine.diagnostic_testAlexithymia; Alexithymia Questionnaire for Children; Migraine; Tension-type headache; Toronto Alexithymia Scale; Adolescent; Analysis of Variance; Case-Control Studies; Child; Female; Humans; Male; Migraine Disorders; Mood Disorders; Mothers; Prevalence; Surveys and Questionnaires; Tension-Type Headache; Anesthesiology and Pain Medicine; Neurology (clinical)General MedicineSettore MED/39 - Neuropsichiatria InfantileFemaleHeadachesmedicine.symptomCase-Control StudieResearch ArticleClinical psychologyHumanmedicine.medical_specialtyMood DisorderAdolescentMigraine Disordersmedia_common.quotation_subjectClinical NeurologyMothersmedicineHumansPersonalityPsychiatryMigraineAnalysis of VarianceMood Disordersbusiness.industryAlexithymia Questionnaire for ChildrenTension-Type Headachemedicine.diseaseAnesthesiology and Pain MedicineMigraineMood disordersCase-Control StudiesToronto Alexithymia ScaleInternational Classification of Headache DisordersNeurology (clinical)businessThe Journal of Headache and Pain
researchProduct

Linguistic characteristics of genetic primary progressive aphasias: a retrospective study of 27 cases carrying GRN and c9orf72 mutations

2018

IF 4.621; International audience

AphasiasClinical Neurology[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC][SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
researchProduct

Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoG…

2019

This multicenter/multinational, open-label, ascending-dose study (NCT01898364) evaluated safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of repeat-dose avalglucosidase alfa (neoGAA), a second-generation, recombinant acid α-glucosidase replacement therapy, in late-onset Pompe disease (LOPD). Patients ≥18 years, alglucosidase alfa naïve (Naïve) or previously receiving alglucosidase alfa for ≥9 months (Switch), with baseline FVC ≥50% predicted and independently ambulatory, received every-other-week avalglucosidase alfa 5, 10, or 20 mg/kg over 24 weeks. 9/10 Naïve and 12/14 Switch patients completed the study. Avalglucosidase alfa was well-tolerated; no deaths…

Avalglucosidase alfa (neoGAA)0301 basic medicineMaleGLUCOSE TETRASACCHARIDELysosomal acid alpha-glucosidase (GAA) deficiencyCHILDRENPulmonary function testingMOTOR FUNCTION0302 clinical medicineMedicineGenetics (clinical)Late-onset Pompe disease (LOPD)Glycogen Storage Disease Type IIAlglucosidase alfaMOUSE MODELEnzyme replacement therapyMiddle AgedTreatment OutcomeNeurologyTolerabilityEnzyme replacement therapySKELETAL-MUSCLEFemaleLife Sciences & BiomedicineMUSCLE TRAINING RMTGlycogen6-MINUTE WALKmedicine.drugAdultmedicine.medical_specialtyClinical NeurologyGLYCOGEN03 medical and health sciencesFEV1/FVC ratioPharmacokineticsInternal medicineHumansEnzyme Replacement TherapyAdverse effectAlglucosidase alfaScience & Technologybusiness.industryNeurosciencesalpha-GlucosidasesADULTSGlycogen storage disease type IISEVERITY030104 developmental biologyPharmacodynamicsPediatrics Perinatology and Child HealthNeurosciences & NeurologyNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular Disorders
researchProduct

Implantation of silicon dioxide-based nanocrystalline hydroxyapatite and pure phase beta-tricalciumphosphate bone substitute granules in caprine musc…

2012

Abstract Background Osteoinductive bone substitutes are defined by their ability to induce new bone formation even at heterotopic implantation sites. The present study was designed to analyze the potential osteoinductivity of two different bone substitute materials in caprine muscle tissue. Materials and methods One gram each of either a porous beta-tricalcium phosphate (β-TCP) or an hydroxyapatite/silicon dioxide (HA/SiO2)-based nanocrystalline bone substitute material was implanted in several muscle pouches of goats. The biomaterials were explanted at 29, 91 and 181 days after implantation. Conventional histology and special histochemical stains were performed to detect osteoblast precurs…

Calcium Phosphateslcsh:Specialties of internal medicineClinical Neurology610 MedizinBiocompatible MaterialsCerasorbHydroxyapatiteOsteogenesislcsh:RC581-951610 Medical sciencesAnimalsSolid-Phase Synthesis TechniquesDentistry(all)GoatsMusclesResearchNanocrystallineSilicon DioxideEctopic bone formationDrug CombinationsDurapatiteß-tricalciumphosphateOtorhinolaryngologyOsteoinductionBone SubstitutesModels AnimalNanoparticlesFemaleNanoBone
researchProduct

Neuropsicología y anorexia nerviosa. Hallazgos cognitivos y radiológicos

2012

Resumen: Introducción: El estudio de las alteraciones neuropsicológicas halladas en pacientes diagnosticadas de anorexia nerviosa (AN) ha experimentado, a través de las últimas décadas, un espectacular avance proporcionando un amplio campo de conocimientos acerca de los cambios observados en la morfología cerebral y las capacidades cognitivas, así como de la reversibilidad o estabilidad de estos, conformando un perfil de alteración neuropsicológico característico de este trastorno de la conducta alimentaria. Desarrollo: Se presenta una revisión actualizada hasta diciembre de 2010 de los resultados obtenidos en la literatura acerca de las alteraciones, tanto de la morfología cerebral como de…

Clinical NeurologyNeurology (clinical)lcsh:Neurology. Diseases of the nervous systemlcsh:RC346-429Neurología
researchProduct